| Literature DB >> 33143143 |
Marlene Fabiola Escobedo-Monge1, Enrique Barrado2, Carmen Alonso Vicente3, María Antonieta Escobedo-Monge4, María Carmen Torres-Hinojal1, José Manuel Marugán-Miguelsanz3, María Paz Redondo Del Río1.
Abstract
Cystic fibrosis (CF) patients require a stable and sufficient supply of micronutrients. Since copper is an essential micronutrient for human development, a cross-sectional study was carried out to investigate the serum copper levels, serum copper/zinc (Cu/Zn) ratios, and their relationship with nutritional indicators in a group of CF patients. Anthropometric, biochemical, and dietary measurements, an abdominal ultrasound, and respiratory and pancreatic tests were conducted. Seventeen CF patients were studied (10 females, 59%), 76.5% of whom were ∆F580. Their mean serum copper (113 ± 23 μg/dL) was normal, and there was only one teenager with hypocupremia (6%) and two children with hypercupremia (18%). A significant association between serum copper and zinc levels was discovered. The Cu/Zn ratio was higher than 1.00 for 94% of patients, which is an indicator of an inflammation status. There was no significant correlation between the serum copper concentrations and respiratory and pancreatic function, respiratory colonization, and the results of the abdominal ultrasound. Linear regression analysis showed that serum copper had a positive association with both the Z-score body mass index (BMI) and mean bone conduction speed (BCS). Therefore, since 94% of CF patients had a Cu/Zn ratio > 1.00, this factor must alert us to consider the risk of zinc deficiency and high inflammatory response. The measurement of serum zinc alone does not show one's zinc status. However, the Cu/Zn ratio may be an indicator of zinc deficiency and the inflammatory status of CF patients.Entities:
Keywords: hypercupremia; hypocupremia; inflammatory response; risk of zinc deficiency; serum copper/zinc ratio
Mesh:
Substances:
Year: 2020 PMID: 33143143 PMCID: PMC7692365 DOI: 10.3390/nu12113344
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Figure 1Flowchart of the cross-sectional study.
Baseline demographic and clinical characteristics of participants (n = 17 *) [30].
| Characteristics | Mean ± SD or | Median | Range |
|---|---|---|---|
| Age (years) | 14.8 ± 8 | 15 | 2–31 |
| Anthropometric Assessment | |||
| Body mass index Z-score | −0.95 ± 1.1 | −0.6 | −3.8 to 0.6 |
| Average conduction velocity Z-score | 0.3 ± 0.9 | −0.0 | −1.6 to 1.4 |
| Indirect Calorimetry (calories) | |||
| Basal energy expenditure | 1078 ± 303 | 1149 | 440–1490 |
| Theoretical basal energy expenditure | 2193 ± 576 | 2200 | 1066–3251 |
| WHO recommended basal energy expenditure | 1185 ± 233 | 1230 | 598–1559 |
| Blood Analytics | |||
| Serum copper level (µg/dL) | 113 ± 23.5 | 113 | 69–158 |
| Serum zinc level (µg/dL) | 87.2 ± 16.7 | 86 | 58–122 |
| Copper/zinc ratio | 1.32 ± 0.28 | 1.33 | 0.73–2.00 |
| Zinc/copper ratio | 0.79 ± 0.18 | 0.75 | 0.5–1.38 |
| Complement C3 (mg/dL) | 117 ± 24 | 110 | 80–165 |
| Complement C4 (mg/dL) | 21 ± 6 | 20 | 15–35 |
| Lymphocytes NK CD16+56 (%) | 10.8 ± 5.8 | 9 | 2–22 |
| Gamma glutamyl transpeptidasa (U/L) | 20.9 ± 19.3 | 13 | 7–70 |
| Prospective Dietary Survey | |||
| Energy intake (calories) | 2595 ± 464 | 2672 | 1846–3410 |
| Vitamin C intake (percentage of dietary reference intake) | 170 ± 141 | 131 | 13–461 |
| Zinc intake (percentage of dietary reference intake) | 97 ± 26.9 | 98 | 54.9–153.9 |
| Comorbidities (%) | |||
| Undernutrition | 5 (29.4%) | ||
| Anemia by iron deficiency | 5 (29.4%) | ||
| Hypocupremia | 1 (5.9%) | ||
| Hypercupremia | 5 (29.4%) | ||
| Hypozincemia | 3 (17.6%) | ||
| Dietary zinc deficiency | 4 (23.5%) | ||
| Abnormal abdominal ultrasound | 5 (29.4%) |
* Seventeen cystic fibrosis patients were screened, included, and analyzed. WHO: World Health Organization.
Differences between fibrosis cystic patients.
| Characteristics | Male | Female | |
|---|---|---|---|
| Age (years) | 10.4 ± 7.2 | 17.2 ± 7.9 | 0.091 |
| Serum copper level (µg/dL) | 109.3 ± 23.4 | 115.7 ± 24.5 | 0.596 |
| Colonization | Yes | No | |
| Serum copper level (µg/dL) | 119 ± 24 | 102.2 ± 19.8 | 0.098 |
| Forced vital capacity | 76.9 ± 24.2 | 94.5 ± 53.7 | 0.478 |
| Forced expired volume in 1 second | 74.9 ± 27.3 | 84.9 ± 27.5 | 0.511 |
| Nutritional Status | Undernutrition | Eutrophic | |
| Serum copper level (µg/dL) | 90 ± 14.1 | 122.7 ± 19.7 | 0.004 |
| Acute Phase Reactants | ERS high | Normal | |
| Serum copper level (µg/dL) | 116.4 ± 20.2 | 112 ± 38.2 | 0.700 |
| Acute Phase Reactants | CRP high | Normal | |
| Serum copper level (µg/dL) | 112.7 ± 23 | 158 | 0.154 |
| Respiratory Function | Sufficient | Insufficient | |
| Serum copper level (µg/dL) | 105.1 ± 23.3 | 120.1 ± 22.5 | 0.277 |
| Dietary zinc intake (%DRI)) | 81.5 ± 20.8 | 112.5 ± 23.6 | 0.015 |
| Pancreatic Function | Sufficient | Insufficient | |
| Serum copper level (µg/dL) | 115.5 ± 29.7 | 112.3 ± 22.6 | 1.000 |
ERS: erythrocyte sedimentation rate; CRP: C reactive protein. %DRI: percentage of dietary reference intake.
Significant correlations and regression analysis between serum copper and nutritional parameters.
| Nutritional Parameters | Serum Copper Level | |||
|---|---|---|---|---|
| Spearman’s Rho Test | Linear Regression Analysis | |||
|
|
| |||
| Body mass index | 0.489 * | 0.046 | 0.236 | 0.048 |
| Average conduction velocity | 0.517 * | 0.040 | 0.275 | 0.037 |
| Vitamin C intake | −0.651 ** | 0.040 | 0.270 | 0.039 |
| Serum zinc | 0.467 | 0.059 | 0.376 | <0.0001 |
| Cardiovascular risk index | 0.51 | 0.045 | 0.26 | 0.045 |
| Complement C3 | 0.616 * | 0.014 | 0.350 | 0.020 |
| Complement C4 | 0.477 ** | 0.001 | 0.535 | 0.002 |
| Lymphocytes NK CD16+56 | 0.559 * | 0.024 | 0.263 | 0.042 |
|
|
|
| ||
|
|
|
|
| |
| Zinc/copper ratio | 0.998 ** | 0.000 | ||
| Protein intake (mg/d) | 0.652 ** | 0.006 | 0.665 ** | 0.005 |
| Monosaturated lipids intake (% DRI) | 0.703 ** | 0.002 | −0.691 | 0.003 |
| Polyunsaturated lipids intake (% DRI) | −0.584 * | 0.018 | 0.584 | 0.018 |
| Niacin intake (% DRI) | 0.641 ** | 0.007 | −0.670 ** | 0.005 |
| Calcium intake (% DRI) | 0.507 * | 0.045 | ||
| Triglycerides | 0.558 * | 0.020 | −0.542 * | 0.025 |
| Serum iron | 0.493 * | 0.045 | ||
| Gamma glutamyl transpeptidase | 0.574 * | 0.016 | −0.573 * | 0.016 |
| Monocytes | −0.532 * | 0.034 | 0.541 * | 0.031 |
Spearman correlation: ** correlation is significant at the 0.01 level (two-tailed), * correlation is significant at the 0.05 level (two-tailed).
Figure 2Regression serum copper and zinc (µg/dL) by age.
Figure 3Regression serum copper (70–140 µg/dL) by zinc (70–120 µg/dL) adjusted for age and cut-offs.
Figure 4Regression serum copper by complement C3.
Figure 5Regression serum copper by complement C4.
Serum copper and iron levels, anemia biomarkers and number of lymphocytes (N = 17 *).
| Age | Serum Copper | Serum Iron | Hemoglobin | Mean Corpuscular Volume | Lymphocytes |
|---|---|---|---|---|---|
| 2 | 113 | 49 | 13.2 | 82 | 6580 |
| 4 | 90 | 79 | 13.8 | 82.6 | 3400 |
| 6 | 158 | 46 | 13.5 | 79.7 | 3830 |
| 8 | 139 | 25 | 15 | 80.8 | 3710 |
| 8 | 108 | 84 | 14.2 | 88.9 | 3440 |
| 9 | 145 | 108 | 14.4 | 85.7 | 2490 |
| 9 | 121 | 79 | 14.35 | 87.8 | 3146 |
| 13 | 121 | 47 | 14.8 | 80.5 | 1900 |
| 15 | 69 | 135 | 14.3 | 89.4 | 1610 |
| 15 | 100 | 69 | 15.1 | 88.5 | 3970 |
| 16 | 105 | 89 | 15.6 | 86.3 | 4120 |
| 18 | 85 | 69 | 11.7 | 92 | 2110 |
| 20 | 113 | 129 | 15.4 | 84.4 | 3200 |
| 23 | 125 | 141 | 17.8 | 96.2 | 2490 |
| 23 | 100 | 45 | 13.4 | 97.8 | 2270 |
| 25 | 139 | 92 | 14.4 | 101.2 | 2920 |
| 31 | 91 | 59 | 13.1 | 89.3 | 2300 |
* 17 cystic fibrosis patients were screened, included and analyzed.